Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer
Executive Summary
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
You may also be interested in...
Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Opdivo/Cabometyx Combo ‘Very Encouraging' In 1L RCC
Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.
Keytruda/Inlyta Data Stoke Competition In Kidney Cancer
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.
Need a specific report? 1000+ reports available
Buy Reports